Protocol Ledger

NCT03959085 · Phase III · RECRUITING

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Interventional Phase III clinical trial protocol NCT03959085 sponsored by Children's Oncology Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-31 Enrollment: 5,951 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03959085
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)5,951 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03959085
Protocol FieldVerified Registry Value
NCT IdentifierNCT03959085
Consolidated Lead SponsorChildren's Oncology Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment5,951 participants (ESTIMATED)
Registered Start Date2019-10-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI